Skip to content

Source filing unavailable

Q1 2024 · —
Revenue—
Net Income-$12.51MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$18.94no prior Q1 2023 on fileno prior Q4 2023 on file
Operating Income-$15,374,000—
Operating Cash Flow-$14,587,000—
Free Cash Flowderived-$14,591,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2024Q1 2023
Net Income-$12.51M-$7.41M
EPS Diluted-$18.94—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR